Finance

Lists
B1SX34:BVMF
Boston Scientific Corp Brazilian Depositary Receipt
R$55,26
0,00%
(0,00) 1D
2 Okt., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for B1SX34...
Open
R$56,55
High
R$56,55
Low
R$55,26
Mkt. cap
61,74 mjd
Avg. vol.
974,00
Volume
502,00
52-wk high
R$140,91
52-wk low
R$50,29
Shares outstanding
1,45 mjd
No. of employees
59 k
Open
R$56,55
High
R$56,55
Low
R$55,26
Mkt. cap
61,74 mjd
Avg. vol.
974,00
Volume
502,00
52-wk high
R$140,91
52-wk low
R$50,29
Shares outstanding
1,45 mjd
No. of employees
59 k
News stories
From web sources and news partners
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp Brazilian Depositary Receipt
CEOMichael F. Mahoney
Employees59 k
Founded29 Jun. 1979
HeadquartersMarlborough, Massachusetts, Verenigde State van Amerika
SectorMedical device
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
5,06 mjd
5,29 mjd
5,20 mjd
5,44 mjd
Cost of goods sold
1,54 mjd
1,61 mjd
1,60 mjd
1,61 mjd
Cost of revenue
1,54 mjd
1,61 mjd
1,60 mjd
1,61 mjd
Research and development expenses
514,00 m
569,00 m
516,00 m
554,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 mjd
1,83 mjd
1,78 mjd
1,80 mjd
Operating expense
2,48 mjd
2,63 mjd
2,53 mjd
2,59 mjd
Total operating expenses
4,02 mjd
4,24 mjd
4,13 mjd
4,20 mjd
Operating income
1,05 mjd
1,04 mjd
1,07 mjd
1,25 mjd
Other non operating income
-16,00 m
28,00 m
28,00 m
-6,00 m
EBT including unusual items
938,00 m
700,00 m
1,16 mjd
1,06 mjd
EBT excluding unusual items
935,00 m
1,01 mjd
999,00 m
1,14 mjd
Income tax expense
183,00 m
30,00 m
-176,00 m
155,00 m
Effective tax rate
19,51%
4,29%
-15,13%
14,62%
Other operating expenses
-
-
-
-
Net income
755,00 m
672,00 m
1,34 mjd
907,00 m
Net profit margin
14,91%
12,71%
25,77%
16,67%
Earnings per share
0,75
0,80
0,80
0,86
Interest and investment income
-
29,00 m
-
11,00 m
Interest expense
-87,00 m
-90,00 m
-90,00 m
-96,00 m
Net interest expenses
-87,00 m
-61,00 m
-90,00 m
-85,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 mjd
1,41 mjd
1,42 mjd
1,60 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme